Capital Cell
Barcelona equity crowdfunding platform for early-stage healthtech and biotech (PFP Capital Cell, S.L.), registered with Spain's CNMV; not FCA-regulated.
Other. receives no payment from the firms it lists. A listing is general information, not a recommendation.
- Minimum investment
- €1,000
- Scale
- €84m invested directly
- Launched
- —
- Geography
- Europe
- Secondary market
- Yes, between investors
- Investment type
- Equity
Capital Cell in ten seconds
Structured fields recorded the same way for every platform in the directory, so they can be compared like for like.
- Asset classes
- Venture Capital
- Investment type
- Equity
- Former FCA appointed representative · Regulated in Spain (CNMV, European crowdfunding service provider licence); former FCA Appointed Representative of Larpent Newton & Company Limited (principal FRN 141275) until 3 Mar 2019 · FCA Register
- Operator
- Pfp Capital Cell, S.L.
- Company status
- Active
- €1,000
- Scale
- €84m invested directlyCompany-reported · Oct 2026€165m in rounds including co-investorsCompany-reported · Oct 2026
- Launched
- —
- Geography
- Europe
- UK investors
- Open to restricted investors (up to 10% of net assets) and sophisticated investorsCompany-reported · Sep 2026
- Yes, between investors
- Operating status
- Active
- Facts checked
- Oct 2026
- Text reviewed
- October 2026
- Website
- capitalcell.com
What is Capital Cell?
Capital Cell is an equity crowdfunding platform for early-stage healthtech and biotech companies, run from Barcelona by PFP Capital Cell, S.L. (tax ID B65998288). Spain's securities regulator, the CNMV, lists it as European crowdfunding service provider no. 12 since 10 November 2023, with permission to offer its services in 26 other EEA countries. The UK is not one of them.
UK history: its UK arm, Capital Cell Ltd (Companies House 10173220, FRN 774677), opened to UK investors in September 2017 as an appointed representative of Larpent Newton & Company Limited. That arrangement ended on 3 March 2019, and the company was dissolved on 17 June 2025 after a members' voluntary liquidation. Capital Cell has never been directly authorised by the FCA.
Scale: its homepage reports 173 completed rounds and a portfolio valued at 2.7 times cost. Its track record page gives €84m invested directly and €165m "in co-investment" (whole rounds including other investors) across 147 companies, 89% of them still in business.
How does Capital Cell work?
Each round has a lead investor who has done its own due diligence. Capital Cell says it publishes about 3% of the companies it analyses (its FAQ puts acceptance at about 1 in 10 applicants). A round must reach 100% of its target; otherwise all money is returned. Until then, investors' money is held by Pecunia Cards E.D.E., S.L.U., an e-money institution authorised by the Bank of Spain.
Most investors hold their shares through Capital Cell's STAK, a Dutch foundation that is the legal owner of the shares while investors hold certificates carrying the economic rights. Spanish taxpayers can instead invest directly to claim Spanish tax relief.
What does Capital Cell offer?
Equity in unlisted healthtech and biotech companies, mostly at pre-seed to Series A, in rounds of up to €5m. On 21 October 2026 it had three live rounds, two of them with a €1,000 minimum; the FAQ says minimums are sometimes as low as €500.
Fees for investors: no fee to invest or for annual STAK management; 8% on transferring certificates before an exit; and 8% of any profit at exit. Companies pay an 8% success fee (minimum €10,000) and an annual SPV fee of €3,084 to €9,000 depending on the amount raised.
Cooling-off: investors can cancel within 7 days of investing and get their money back without giving a reason.
Who is Capital Cell for?
Investors who understand early-stage life-sciences risk and can wait years for an exit. Capital Cell's own FAQ describes the trade-off: a hoped-for return of 200% to 1,000% that cannot be recovered for 2 to 6 years, with "a 1 in 3 chance of making a profit". To invest more than €1,000 in a round, investors must first pass a short knowledge test. It is a European platform with no UK authorisation, so UK investors have no FCA, FSCS or Financial Ombudsman protection for current investments.
Regulatory status and complaint handling
Capital Cell is supervised in Spain by the CNMV under the EU crowdfunding regulation, and its terms are governed by Spanish law with Barcelona courts. Complaints go to info@capitalcell.net within two months of the problem coming to light; Capital Cell aims to resolve them within two months. For business done while Capital Cell Ltd was an appointed representative (2017 to 2019), the FCA Register says a claim may be possible through the former principal firm.
What stands out, and what to weigh against it
specialist focus with a lead investor in every round, low minimums, published investor fees and a portfolio record with named exits (including Vytrus Biotech's listing and GoodGut's sale to HIPRA).
most early-stage biotech companies fail or take many years to exit, and Capital Cell's 2.7x portfolio value is mostly unrealised. Exits are mainly through a sale or listing of the company.
This is Other.'s editorial assessment based on the information reviewed. It is not a recommendation.
Before you go further
Points we would verify against the platform's current documents rather than take from this page.
- Selling early
the secondary market is a notice board where sellers and buyers find each other; the company and its founders have a right of first refusal, and the STAK charges 8% on a transfer before exit.
- Scale wording
the homepage's "165M€ Total Invested" counts whole rounds including other investors; money invested through the platform is €84m.
- Mixed selection figures
the homepage says 3% of companies are selected; the FAQ says about 1 in 10 applicants.
Sources and methodology
- Text reviewed
- October 2026
- Sources
- capitalcell.com (home, track record, FAQ, STAK, conditions for promoters, terms, fetaLife and VRAIn Medical rounds, checked 21 October 2026); CNMV crowdfunding provider register (no. 12); FCA Register (Capital Cell Ltd, FRN 774677); Companies House (10173220); Capital Cell press release via BioSpace (20 September 2017)
- Methodology
- How we research platforms →
Editorial research, not financial advice. See the full disclaimer in the site footer. Are you the owner of Capital Cell or representing the company? To submit an addition, clarification or correction, get in touch or use our contact form.
Capital Cell vs other Venture Capital platforms
| Capital Cell | Prospedia Capital | Republic Europe (formerly Seedrs) | Crowdcube | |
|---|---|---|---|---|
| Minimum | €1,000 | Not disclosed | £/€20 | £10 |
| FCA status | Former FCA appointed representative | Former FCA appointed representative | FCA authorised | FCA authorised |
| Structure | Equity | Equity | Equity, Convertibles | Equity |
| Secondary market | Yes, between investors | No | Yes, between investors | At set trading windows |
| Launched | — | 2020 | 2012 | 2011 |
| Geography | Europe | UK | UK & Europe | UK & Europe |
- What is the minimum investment on Capital Cell?
- Capital Cell's minimum investment is €1,000.
- Is Capital Cell regulated by the FCA?
- Not any more. Regulated in Spain (CNMV, European crowdfunding service provider licence); former FCA Appointed Representative of Larpent Newton & Company Limited (principal FRN 141275) until 3 Mar 2019.
- Does Capital Cell offer a secondary market?
- Yes. Capital Cell lets investors list holdings for sale to other investors before they mature. A sale depends on another investor wanting to buy, so it isn't guaranteed, and the price can be below what you paid.